The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Pharmacodynamic Assays, 2013Monocyte Monitoring in LRRK2-associated Parkinson’s Disease
Objective/Rationale:
LRRK2 variants significantly contribute to the development of familial and sporadic Parkinson’s disease (PD). However, it is not yet understood how LRRK2 mutations cause cellular... -
Research Grant, 2013Evaluation of a LRRK2 Inhibitor in the Partial 6-OHDA-lesioned Model of Parkinson’s Disease
Objective/Rationale:
Mutations in the LRRK2 gene are the most common cause of familial Parkinson’s disease (PD). The existing human genetic, cell-based and model data suggest that LRRK2 kinase... -
Research Grant, 2013Using Whole Genome Sequencing Data from LRRK2 Families to Identify Novel Rare Variants of LRRK2-associated Parkinson’s Disease
Objective/Rationale:
The age of onset and penetrance (likelihood of disease) of individuals with the LRRK2 G2019S mutation varies considerably, the latter ranging in some families from as high as 100... -
Research Grant, 2011Pre-clinical Development of Encapsulated Cell Biodelivery of GDNF for Parkinson's Disease
Objective/Rationale:
Glial cell line-derived neurotrophic factor (GDNF) is a protein that can aid in survival of the dopamine cells that die in Parkinson’s disease (PD). Treatment with GDNF in PD has... -
Biomarker Development, 2015Development of Novel, Small Molecule Compounds as PET Tracers for Synucleinopathies
Study Rationale:
Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson’s disease (PD) pathology. Such an agent will help (i) diagnose PD earlier,... -
Target Validation, 2014Dual GluK1/GluK3 Antagonism as a Neuroprotective Target
Objective/Rationale:
Over activation of glutamate receptors may contribute to the loss of dopamine cells in Parkinson’s disease (PD). Research suggests that drugs that target these...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.